The packet contains no diagnostic methods or diagnostic criteria, so diagnostic approaches are not described here.

The packet certifies no FDA-approved treatments, foundational therapies, or GeneReviews management content. Its orphan-drug records include Omega-3 (n-3) polyunsaturated fatty acids (sponsor Pronova Biocare, AS) with status DESIGNATED for treatment of IgA nephropathy; an orphan designation is not an approval. Other orphan-drug records in the packet list a different indication and are not described here.

Prognosis is not certified in this packet. It contains no natural history or outcome information, and none is stated here.

ClinicalTrials.gov records in the packet include NCT05797610, a phase 3 study of sefaxersen (RO7434656) in participants with primary IgA nephropathy at high risk of progression (Hoffmann-La Roche), listed as active, not recruiting, 2023-08-08 to 2029-08-31. NCT07498335, a phase 3 study of atrasentan in pediatric patients with primary IgAN (Novartis), is listed as recruiting, 2026-08-06 to 2032-12-13. NCT06989359, a phase 2 study of ADX-038 in complement-mediated kidney disease (ADARx Pharmaceuticals, Inc.), is listed as recruiting, 2025-08-28 to 2029-06-01. Several other records are listed as not yet recruiting, and their current status is not verified here. Trial titles do not establish intervention effects.